Epilive 500 Tablet contains Levetiracetam 500mg, an antiepileptic agent indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. Epilive 500 is commonly prescribed as adjunctive therapy in adults and pediatric patients aged four years and above. The tablet is administered orally, with dosage individualized based on patient response and clinical condition, typically starting at a lower dose and titrated accordingly. Common adverse effects may include somnolence, dizziness, headache, and fatigue, though it is generally well tolerated. Caution is advised in patients with renal impairment, as dose adjustment may be necessary. Epilive 500 should be used under medical supervision, with regular monitoring to assess efficacy and tolerability. It is essential to adhere to prescribed dosing schedules and not discontinue therapy abruptly to prevent seizure exacerbation. This medication does not cure epilepsy but helps control seizures, improving quality of life for affected individuals. Patients should inform their healthcare provider of any other medications or medical conditions prior to initiating treatment.